|
- Aducanumab Discontinued as Alzheimer’s Treatment | alz. org
Aducanumab (Aduhelm®), which received accelerated approval as a treatment for Alzheimer's disease from the U S Food and Drug Administration (FDA) in 2021, has been discontinued by its manufacturer (Biogen)
- Aducanumab - Wikipedia
Aducanumab, sold under the brand name Aduhelm, is an anti-amyloid drug designed to treat Alzheimer's disease [1][2] It is a monoclonal antibody [2][1] that targets aggregated forms (plaque) [3][4] of amyloid beta (Aβ) found in the brains of people with Alzheimer's disease to reduce its buildup [5][6] It was developed by Biogen and Eisai [7]
- Aduhelm: What to Know - WebMD
Aducanumab (Aduhelm) is a discontinued drug for Alzheimer’s disease with mild cognitive impairment It’s a monoclonal antibody that works by removing amyloid proteins – substances that build up
- Biogen discontinues Alzheimer’s medication Aduhelm - CNN
The Alzheimer’s medication Aduhelm is being discontinued by drugmaker Biogen as it shifts resources to its other Alzheimer’s medication, Leqembi, and developing other treatments, the company said
- Aduhelm: Uses, Dosage, Side Effects, Warnings - Drugs. com
Aduhelm is used to treat people with Alzheimer’s disease who have mild cognitive impairment (MCI) or mild dementia Aduhelm injection belongs to a class of medications called monoclonal antibodies It works by blocking the formation of amyloid beta in the brain
- Alzheimer’s Drug Aduhelm Pulled Off the Market - AARP
Drugmaker Biogen has announced that it plans to stop selling Aduhelm, an Alzheimer’s treatment that received a fast-tracked approval from the Food and Drug Administration (FDA) in 2021 The company will also end its clinical trial testing the drug, which was required for full FDA approval
- What the End of Aduhelm Means for Alzheimers Treatment
Biogen has announced that it will discontinue sales and an ongoing clinical trial for the Alzheimer’s drug Aduhelm Here's what to know, and what treatment options remain available
- Aduhelm: Biogen abandons Alzheimer’s drug after . . . - The BMJ
The US drug company Biogen is walking away from its Alzheimer’s drug aducanumab (Aduhelm) Aduhelm was once billed as history’s greatest blockbuster drug, but ended up generating almost no income after insurers refused coverage and clinicians chose not to prescribe it
|
|
|